Department of Breast, Nanjing Maternity and Child Health Hospital, Nanjing Medical University, People's Republic of China.
BMC Cancer. 2012 Aug 28;12:374. doi: 10.1186/1471-2407-12-374.
Different ethnicities have different distribution of Duffy blood group (DBG) phenotypes and different breast cancer morbidity. A study in our lab demonstrated that Duffy antigen/receptor for chemokines (DARC, also known as DBGP, the Duffy protein phenotype), led to the inhibition of tumorigenesis. Therefore, we tested the hypothesis that DBGP is correlated with breast cancer occurrence.
DBGP proteins were examined by indirect antiglobulin testing with anti-FYa and anti-FYb antibodies. The phenotypes were classified into four groups according to the agglutination reactions: FYa + FYb+, FYa + FYb-, FYa-FYb + and FYa-FYb-. The phenotypes and pathological diagnosis of consecutively hospitalized female patients (n = 5,022) suffering from breast cancer at the Shanghai Cancer Hospital and Henan Province Cancer Hospital were investigated. The relationships between DBGP expression with breast cancer occurrence, axillary lymph status, histological subtype, tumor size pathological grade and overall survival were analyzed.
The incidence of breast cancer was significantly different between FYa + FYb + (29.8%), FYa + FYb- (33.2%), FYa-FYb + (45.6%) and FYa-FYb- (59.1%; P = 0.001). Significant different numbers of breast cancer patients had metastases to the axillary lymph nodes in the FYa + FYb + group (25.1%), FYa + FYb- (36.9%), FYa-FYb + (41.0%) and FYa-FYb- (50.0%, (P = 0.005). There was a statistical significance (p = 0.022) of the overall survival difference between patients with difference phenotypes. No significant difference was observed in cancer size (t-test, p > 0.05), histological cancer type (Fisher's exact test, p > 0.05) or histological grade (Fisher's exact test, p > 0.05) between every each DBGP group.
DBGP is correlated with breast cancer incidence and axillary lymph node metastasis and overall survival. Further investigations are required to determine the underlying mechanism of Duffy blood group phenotype on breast cancer risk.
不同种族的人具有不同的达菲血型（DBG）表型分布，乳腺癌发病率也不同。我们实验室的一项研究表明，达菲抗原/趋化因子受体（DARC，也称为 DBGP，达菲蛋白表型）抑制肿瘤发生。因此，我们检验了 DBGP 与乳腺癌发生相关的假设。
使用抗-FYa 和抗-FYb 抗体通过间接抗球蛋白试验检查 DBGP 蛋白。根据凝集反应将表型分为四组：FY a + FY b +、FY a + FY b-、FY a-FY b +和 FY a-FY b-。调查了在上海癌症医院和河南省癌症医院连续住院的女性乳腺癌患者（n = 5022）的表型和病理诊断。分析了 DBGP 表达与乳腺癌发生、腋窝淋巴结状态、组织学亚型、肿瘤大小病理分级和总生存的关系。
FY a + FY b +（29.8%）、FY a + FY b-（33.2%）、FY a-FY b +（45.6%）和 FY a-FY b-（59.1%）组乳腺癌发病率差异有统计学意义（P = 0.001）。FY a + FY b +组（25.1%）、FY a + FY b-（36.9%）、FY a-FY b +（41.0%）和 FY a-FY b-（50.0%）组乳腺癌患者腋窝淋巴结转移的数量差异有统计学意义（P = 0.005）。不同表型患者的总生存率差异有统计学意义（p = 0.022）。在癌症大小（t 检验，p > 0.05）、组织学癌症类型（Fisher 确切检验，p > 0.05）或组织学分级（Fisher 确切检验，p > 0.05）方面，每个 DBGP 组之间均无显著差异。
DBGP 与乳腺癌的发生、腋窝淋巴结转移和总生存率有关。需要进一步研究以确定达菲血型表型对乳腺癌风险的潜在机制。
